ReviewHeadache2008
Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine.
Review in Headache, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.European journal of medical research · 2022Pooled it
- Neurogasobiology of migraine: Carbon monoxide, hydrogen sulfide, and nitric oxide as emerging pathophysiological trinacrium relevant to nociception regulation.Open medicine (Warsaw, Poland) · 2025Review
- The Epigenetics of Migraine.International journal of molecular sciences · 2023Review
- Excitatory Effects of Calcitonin Gene-Related Peptide (CGRP) on Superficial Sp5C Neurons in Mouse Medullary Slices.International journal of molecular sciences · 2021Article
- Bio-OssExperimental and therapeutic medicine · 2017Article
- Activity of botulinum toxin type A in cranial dura: implications for treatment of migraine and other headaches.British journal of pharmacology · 2016Article
- Therapeutic antibodies against CGRP or its receptor.British journal of clinical pharmacology · 2015Review
- [(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.ACS medicinal chemistry letters · 2013Article
- Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres.Neuropharmacology · 2012Article
- Article
- Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia.Cephalalgia : an international journal of headache · 2011Article
- Calcitonin gene-related peptide-mediated enhancement of purinergic neuron/glia communication by the algogenic factor bradykinin in mouse trigeminal ganglia from wild-type and R192Q Cav2.1 Knock-in mice: implications for basic mechanisms of migraine pain.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- Epoxyeicosatrienoic acids are endogenous regulators of vasoactive neuropeptide release from trigeminal ganglion neurons.Journal of neurochemistry · 2010Article
- The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects.Archives of drug information · 2010Article
- Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.ACS medicinal chemistry letters · 2010Article
- Facilitation of synaptic transmission and pain responses by CGRP in the amygdala of normal rats.Molecular pain · 2010Article
- Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons.Journal of cell science · 2009Article
- Sinus problems as a cause of headache refractoriness and migraine chronification.Current pain and headache reports · 2009Review
- Review
- A Potential Preclinical Migraine Model: CGRP-Sensitized Mice.Molecular and cellular pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The neuropeptide calcitonin gene-related peptide (CGRP) is implicated in the underlying pathology of migraine. Serum levels of CGRP, which are elevated during a migraine attack, have been reported to return to normal with alleviation of pain. In addition, CGRP administration has been shown to cause a migraine-like headache in susceptible individuals. Importantly, CGRP receptors are found on many cell types within the trigeminovascular system that are thought to play important roles in controlling inflammatory and nociceptive processes. Based on these findings, it was proposed that blockage of CGRP receptor function and, hence, the physiological effects of CGRP would be effective in aborting a migraine attack. This review will summarize key preclinical data that support the therapeutic potential of using CGRP receptor antagonists or molecules that bind CGRP within the context of current neurovascular theories on migraine pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.